FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Olagunju Peter  (Last) (First) (Middle)  C/O TCR2 THERAPEUTICS  100 BINNEY STREET						Suer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [ TCRR ]  3. Date of Earliest Transaction (Month/Day/Year) 12/09/2022										Officer (since title				ssuer wner specify
(Street) CAMBR (City)	IDGE N	√IA State		)2142 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person											on			
			Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or B	enef	icially	/ Own	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Exec if any	Deemed ecution Date, ny onth/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Securi Benef Owner		cially Following	Forn (D) c	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) (D)	Pri	ce		rted saction(s) . 3 and 4)			(Instr. 4)				
Common Stock																28	28,922		D	
Common Stock 12/09/2						2022				<b>S</b> <sup>(1)</sup>		1,561	D	\$1	1.131	1 27,361			D	
Common Stock 12/12/2						.022				<b>S</b> <sup>(1)</sup>		1,610	D	\$	1.097	2:	5,751		D	
Common Stock 12/13/2					2022				<b>S</b> <sup>(1)</sup>		1,659	D	\$	1.065	65 24,092			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	Date (Month/Day/Year) Price of Derivative Security  Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)					ite	Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In tr.	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

## **Explanation of Responses:**

## Remarks:

/s/ Margaret Siegel as Attorney-in-Fact

12/13/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.